Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for emergence agitation after pediatric adenotonsillectomy
ACTRN12618000963224Phase 4Completed
- Sponsor
- Semra Gumus Demirbilek
- Start
- Jun 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Emergence agitation (EA) comparing Sugammadex with Neostigmine + atropine (2 arms). Primary endpoints: Emergence agitation by PAED scale and Emergence agitation by agitation scale. Started Jun 2018; status: completed.
02
Drugs
Sugammadexneostigmineatropine
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on ACTRN12618000963224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000963224.